**Evidence Table 6. Benefits (KQ1 & 2)**

|  |  |  |
| --- | --- | --- |
| Author,  Year,  Trial Name | Prevention or Reduction in Physical Health Conditions or Symptoms | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Ahrens, 20021  NA | NR | NR |
| Berger, 20072  OTT | DPS (range: 0-6), Mean  G1: 2.1 (SD=1.7)  G2: 1.9 (SD=1.6)  Within group change at post-treatment:  G1: -1.0 (calculated)  G2: 0.1 (calculated)  Between group change at post-treatment: -1.1 (calculated)  Between group ANOVA: F=40.44, df=1,140, p<0.001 | NR |
| Berger, 20093  ES-SL | DPS (range: 0-5), Mean Pretreatment  G1: 1.46 (SD=1.0)  G2: 1.26 (SD=1.0)  Within group change at post-treatment:  G1: -0.82 (calculated)  G2: 0.19 (calculated)  Between group change at post-treatment: -1.01 (calculated)  Between group ANOVA: F=44.80, df=1,164, p<0.001 | NR |
| Berkowitz, 20114  NA | NR | NR |
| Catani, 20095  NA | # of physical symptoms  Pretreatment  G1: 1.75 (SD=1.34) G2: 1.80 (SD=1.26) Within group change at post-treatment assessment:  G1: -0.25 (calculated)  G2: -1.13 (calculated)  Within group change at 6 Mos.:  G1: -0.25 (calculated)  G2: -0.51 (calculated)  Between group change at post-treatment assessment:  0.88 (calculated) Repeated measures ANOVA for time\*treatment interaction p=NS  Between group change at 6 Mos. assessment: 0.26 (calculated)  Repeated measures ANOVA for time\*treatment interaction p=NS | NR |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author,  Year,  Trial Name | Prevention or Reduction in Physical Health Conditions or Symptoms | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Ford, 20126  TARGET | NR | NR |
| Gelkopf, 20097  ERASE-Stress | DPS (range 0-5), Mean Pretreatment  G1: 2.1 (SD=1.3)  G2: 1.9 (SD=1.2)  Within group change at post-treatment:  G1: -1.0 (calculated)  G2: unknown based on data reporting error  Between group change at post-treatment: unknown based on data reporting error  Between group ANOVA: F=24.07, df=1,106, p<0.001 | NR |
| Goenjian, 1997; 20058, 9  NA; NA | NR | NR |
| Jaycox, 200910  SSET | NR | NR |
| Kemp, 201011  NA | GHQ-12-General Health (range: 0-12)  Pretreatment  G1: 1.09 (SD=1.92)  G2: 4.25 (SD=4.11)  Within group change:  G1: 0.82 (calculated)  G2: -0.42 (calculated)  Between group change: 1.24 (calculated)  p=NS | CBCL, Parent rating (range: 30-100),  Pretreatment  G1: 36.73 (SD=22.49)  G2: 30.10 (SD=34.16)  Within group change:  G1: -8.28 (calculated)  G2: 13.07 (calculated)  Between group change (95% CI): -21.35 (calculated)  p=NS |
| Layne, 200812  TGCT | NR | NR |
| Nugent, 201013  NA | No between group difference in heart rate during or after trauma narrative p=NS  No other data given | NR |
| Robbd, 201014  NA | NR | NR |
| Roberte, 199915  NA | NR | NR |
| Robertf, 200816  NA | NR | NR |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author,  Year,  Trial Name | Prevention or Reduction in Physical Health Conditions or Symptoms | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Salloumg, 200817  NA | NR | NR |
| Salloum, 201218  NA | NA | CBCL (range: NR), t-score of 63+ (clinically significant parent-reported internalizing problem behavior)  Pretreatment:  G1: 20.5%  G2: 12.1%  Within group change at 12 Mos. assessment:  G1: -14.6%  G2: 1.2%  Between group change at 12 Mos. assessment: 15.8%, p=NR  CBCL, Parent-reported Internalizing symptoms Pretreatment: G1: 9.50 (SD=7.33) G2: 8.76 (SD=5.69) Within group change at post-treatment assessment:  G1: NR G2: NR  Between group change at post-treatment assessment: NR Within group change at 3 Mos. assessment:  G1: -2.00, d=0.29, p=NR G2: -1.33, d=0.21, p=NR  Between group change at 3 Mos. assessment: -0.67, p=NR Within group change at 12 Mos. assessment:  G1: -3.61, d=0.58, p=NR (RCI: 17.86% improved, 0% deteriorated) G2: -1.52, d=0.26, p=NR (RCI: 14.29% improved, 4.76% deteriorated)  Between group change at 12 Mos. assessment: -2.09, ANOVA time\*treatment interaction p=NR; RCI difference p=NR Internalizing symptoms changed over time, F(2,94)=4.46, p=0.015 for both treatment conditions.  CBCL, Parent-reported Externalizing symptoms Pretreatment: G1: 12.39 (SD=7.49) G2: 10.05 (SD=8.73) Within group change at post-treatment assessment:  G1: NR G2: NR |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author,  Year,  Trial Name | Prevention or Reduction in Physical Health Conditions or Symptoms | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Salloum, 201218 |  | Between group change at post-treatment assessment: NR Within group change at 3 Mos. assessment:  G1: 0.97, d=0.12, p=NR G2: 0.05, d=0.006, p=NR  Between group change at 3 Mos. assessment: 0.92, p=NR Within group change at 12 Mos. assessment:  G1: -2.78, d=0.35, p=NR G2: 0.57, d=0.06, p=NR  Between group change at 12 Mos. assessment: -2.21, ANOVA time\*treatment interaction using ITT analysis: F(2,108)=3.81, p=0.026 |
| Smith, 200719  NA | NR | NR |
| Stein, 200320  NA | NR | NR |
| Tol, 2008; 2010 21, 22 NA | NR | Parent-rated Children’s Aggression Scale for Parents (range: 33-132)  Pretreatment  G1: 42.18 (SD=9.09)  G2: 44.63 (SD=12.08)  Within group change at 1 week:  G1: -1.44 (SD=4.72)  G2: -1.16 (SD=4.23)  Within group change at 6 Mos.:  G1: -2.03 (SD=4.71)  G2: -1.48 (SD=4.69)  Between group difference at 1 week (95% CI): d=0.06 (-0.13, 0.25)  Between group difference at 6 Mos. (95% CI): d=0.12 (-0.07, 0.31) |
| Tol, 201223  NA | NA | Conduct problems:  Pretreatment:  G1: 2.00 (SD=2.84)  G2: 1.99 (SD=2.23)  Within group change at post-treatment:  G1: NR  G2: NR  Between group change at post-treatment: NR  LGCM estimate (SE): -0.132 (0.045); p<0.01 |

Evidence Table 6. Benefits (KQ1 & 2) (continued)

|  |  |  |
| --- | --- | --- |
| Author,  Year,  Trial Name | Prevention or Reduction in Physical Health Conditions or Symptoms | Reduction in Risk-Taking Behaviors, Behavioral Problems, or Criminal Activities |
| Zehnder, 201024  NA | NR | CBCL-German version (range: NR), Mean  Pretreatment:  G1: 53.4 (SD=9.3)  G2: 50.6 (SD=9.1)  Within group change at Time 1 assessment:  G1: -3.4 (calculated)  G2: -0.6 (calculated)  Between group change at Time 1 assessment: -2.8 (calculated)  Within group change at Time 2 assessment:  G1: -2.6 (calculated)  G2: -1.8 (calculated)  Between group change at Time 2 assessment: -0.8 (calculated)  Repeated measures ANOVA treatment\*time interaction: F=0.01, p=NS |

Note: No eligible study reported on decreased suicidality in the context of KQ1 or KQ2.

Abbreviations: CBCL = Child Behavior Checklist; CI = confidence interval; d = effect size; df = degrees of freedom; DPS = DISC Predictive Scales; ERASE-Stress – Enhancing Resilience among Students Experiencing Stress; ES-SL = ERASE Stress Sri Lanka; G = group; GHQ-12; General Health Questionnaire; ITT = Intent-to-treat; LGCM = latent growth curve modeling; Mos. = months; NA = not applicable; NR = not reported; NS = not significant; OTT = Overshadowing the Threat of Terrorism; RCI – Reliable Change Index; SD = standard deviation;; SE = standard error; SSET = Support for Students Exposed to Trauma; TARGET = Trauma Affect Regulation: Guide for Education and Therapy; TGCT = Trauma and Grief Component Therapy.